Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Impilo on the establishment of a continuation fund
Mandate

Vinge advises Impilo on the establishment of a continuation fund

November 15, 2024

Vinge has advised Impilo with regulatory advice on the establishment of Impilo Orphan Drugs, a so-called continuation fund. The continuation fund will have EUR 320m in commitments and will invest in Immedica, in which KKR recently became an owner alongside Impilo.

Impilo is a Nordic investment company specializing in investments within the pharmaceutical, medical technology, healthcare services and other health-related industries. Impilo holds a highly diversified portfolio of healthcare investments and manages approximately EUR 1 billion in capital, from leading Nordic and international investors.

Vinges team consisted of Nils Unckel, Anton Sjökvist and Viktoria Wnuk.

Related

Vinge advises the sellers on the sale of Nextory to Bonnier Books

 Vinge has acted as legal adviser to the sellers in connection with Bonnier Books’ acquisition of Nextory, one of Europe’s leading streaming services for audiobooks and e-books. Bonnier Books is acquiring all shares in Nextory, and the transaction comprises Nextory’s operations in Sweden and internationally. The acquisition is a cash transaction and the parties have agreed not to disclose the purchase price. The transaction is subject to customary regulatory approvals.
September 02, 2026

Vinge has advised Nimlas in connection with six strategic acquisitions that strengthen the group's position in the Swedish installation market

 Nimlas, with KLAR Partners as majority owner, is one of the Nordic region's leading installation groups, comprising close to 140 companies and 5,000 employees in Sweden, Finland and Norway.
September 02, 2026

Vinge has advised Aspira Partners on the establishment of Aspira Fund I

 Vinge has advised Aspira Partners ("Aspira") on the establishment and fundraising of Aspira's inaugural blind-pool fund, Aspira Fund I (D) AB and Aspira Fund I (E) AB (collectively, "Fund I" or the "Fund").
August 31, 2026